The global rollout of COVID-19 vaccines will be the largest, fastest and most challenging vaccination program in history. This could bring many problems. Some we will anticipate; some we won’t. One glaring problem that is quickly emerging is a major mismatch between vaccine supply and demand. Initial hesitancy among the public about getting vaccinated is rapidly transitioning to a growing demand for immediacy and a global stampede for access to vaccines is gaining speed. This means that access to vaccines is only going to get tighter, regardless of the number of vaccines approved by various governments. It is simply a matter of mathematics.

This is a whipsaw transition in what many authorities and experts initially thought would be the biggest challenge for vaccine rollout – vaccine hesitancy. Social media and the dark corners of the internet are full of conspiracy theories about the motivations behind mass vaccination and the potential risks of being vaccinated. As recent events in many countries have shown, these theories and their advocates can influence public opinion.
Until recently, most polling supported the view that hesitancy could become a significant challenge for vaccine rollout. But it seems we were getting the wrong signal from the data. Hesitancy wasn’t being driven by the public buying into conspiracy theories, it was more likely to be reasonable, thoughtful people being hesitant because they didn’t know what they needed to know to make the right decision. Many of the world’s citizens reported they were worried about the speed at which new vaccines have been approved and their potential health risks, both immediate and longer-term. For the more cautious among us this was an honest, logical reaction to an information and experience deficit. We simply didn’t know what we needed to know to make the decision to get vaccinated.

What we now see is that early success with vaccines is building confidence among the public to roll up their sleeves. Every day of success is building confidence in vaccines and increasing demand.

Our most recent polling on willingness to get the vaccine shows a remarkable increase in the percent of respondents across 15 countries who strongly agree that “if a vaccine were available to me, I would get it.” Unlike in the prior waves, the January 2021 results exclude those who indicate they have received either one or both doses (if required) of the vaccine which tops out at 13% among respondents from China, followed by 10% of those in US who indicate they have been vaccinated.
Among those who agree they would get the vaccine for COVID-19, a majority would opt to receive it within a month, with 44 percent indicating they would get it “immediately”. The Japanese seem to be the most hesitant to be vaccinated. This is a trend we have seen in previous surveys. Also, while France continues to be below average on willingness to get vaccinated, those who are willing are ready to roll up their sleeves quickly.

Groups most interested in getting to the front of the line for vaccines include older citizens, the more affluent and those who have higher trust in government. We find overall that men are more likely than women to be willing to get the vaccine, although among younger age groups, the gap evens out.

Where to from here?

Unmet demand threatens to increase public anxiety. The emerging challenge will be convincing large segments of the public it is reasonable and acceptable to patiently wait their turn. This mismatch between the public’s expectations and the capability to deliver vaccines isn’t a significant problem yet. Most global citizens are content for now to wait for the most essential and most vulnerable among us to go first. But this patience won’t last. At some point the public will begin to wonder when their turn will come. That’s when the questions about how vaccines

![FIG 2: TIMEFRAME FOR GETTING VACCINATED](chart.png)

Q. Once the COVID-19 vaccine becomes available to you, when would you get the vaccine?

<table>
<thead>
<tr>
<th>Country</th>
<th>Immediately</th>
<th>Less than one month</th>
<th>One month to less than three months</th>
<th>3 months to less than 6 months</th>
<th>6 months or more</th>
<th>Not sure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brazil</td>
<td>62%</td>
<td>11%</td>
<td>10%</td>
<td>6%</td>
<td>4%</td>
<td>7%</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>65%</td>
<td>9%</td>
<td>7%</td>
<td>4%</td>
<td>4%</td>
<td>10%</td>
</tr>
<tr>
<td>China</td>
<td>23%</td>
<td>22%</td>
<td>27%</td>
<td>12%</td>
<td>11%</td>
<td>5%</td>
</tr>
<tr>
<td>Mexico</td>
<td>58%</td>
<td>15%</td>
<td>11%</td>
<td>8%</td>
<td>6%</td>
<td>2%</td>
</tr>
<tr>
<td>Italy</td>
<td>55%</td>
<td>11%</td>
<td>9%</td>
<td>9%</td>
<td>10%</td>
<td>5%</td>
</tr>
<tr>
<td>Canada</td>
<td>50%</td>
<td>13%</td>
<td>9%</td>
<td>9%</td>
<td>10%</td>
<td>9%</td>
</tr>
<tr>
<td>South Korea</td>
<td>14%</td>
<td>14%</td>
<td>26%</td>
<td>21%</td>
<td>20%</td>
<td>5%</td>
</tr>
<tr>
<td>Spain</td>
<td>54%</td>
<td>13%</td>
<td>12%</td>
<td>7%</td>
<td>7%</td>
<td>8%</td>
</tr>
<tr>
<td>Australia</td>
<td>40%</td>
<td>16%</td>
<td>15%</td>
<td>10%</td>
<td>8%</td>
<td>10%</td>
</tr>
<tr>
<td>Germany</td>
<td>55%</td>
<td>10%</td>
<td>14%</td>
<td>8%</td>
<td>7%</td>
<td>7%</td>
</tr>
<tr>
<td>Japan</td>
<td>22%</td>
<td>13%</td>
<td>15%</td>
<td>12%</td>
<td>15%</td>
<td>22%</td>
</tr>
<tr>
<td>US</td>
<td>53%</td>
<td>17%</td>
<td>9%</td>
<td>8%</td>
<td>5%</td>
<td>8%</td>
</tr>
<tr>
<td>France</td>
<td>42%</td>
<td>14%</td>
<td>15%</td>
<td>10%</td>
<td>12%</td>
<td>6%</td>
</tr>
<tr>
<td>South Africa</td>
<td>43%</td>
<td>15%</td>
<td>10%</td>
<td>8%</td>
<td>8%</td>
<td>15%</td>
</tr>
<tr>
<td>Russia</td>
<td>23%</td>
<td>20%</td>
<td>19%</td>
<td>9%</td>
<td>15%</td>
<td>13%</td>
</tr>
</tbody>
</table>

Base: 12,777 online adults aged 16-74 across 15 countries (excludes those who report receiving the vaccine), conducted January 14 to 17, 2021* Online samples in Brazil, China, Mexico, Russia, and South Africa tend to be more urban, educated, and/or affluent than the general population.
have been managed by our public authorities will get sharper.

Adding to these worries is that most people are looking at vaccines from a local perspective. Warnings from global authorities about the lack of access for developing countries have fallen on deaf ears. This could quickly turn into a zero-sum game in which vaccines going to other countries could be seen as vaccines being denied to your local family and neighbours. This could especially be the case in countries blessed with their own vaccine manufacturing capacity.

**Stages of vaccine rollout**

We envision three main stages in the process of rolling out COVID-19 vaccines for the world:

**Phase 1:** Demand over supply

**Phase 2:** Activating the hesitant

**Phase 3:** Reaching herd immunity/sustaining behaviours

The first stage will be how to manage the temporary shortage of vaccines as demand escalates. Focusing on the vulnerable and the most necessary is key to keeping the public on side in the short-term. But in the not too distant future vaccinations will move out to the wider public. That’s when clarity about process and managing expectations about access at a very personal level becomes most important. Stated simply, knowing exactly how long it will be until you roll up your sleeve is better than any general statement about timely access.

As initial demand subsides there is a strong behavioural science-based route to bringing the ‘reasonable reluctant’ on side with vaccination. To summarise, it is a combination of regretting what not getting vaccinated could do to others, trusted information sources addressing specific concerns, and creating identities and social norms associated with getting vaccinated. Personal choice is also an important part (reasonable people like you are choosing to be vaccinated against COVID-19).

The last mile for vaccines will be convincing those who are especially reluctant and unlikely to participate. Our analysis in Figure 1 suggests this remains a sizeable number (20%-30%) in many countries. Of the countries in our study this wave, citizens of Russia (54% disagree they would get the vaccine), South Africa (49%) and France (45%) are the most reluctant to be vaccinated, followed by the US (37%) and Japan (36%). However, given the strong early demand for vaccines, focusing communications on this group at this time may not be a priority.
Vaccine messaging: Using a behavioural science approach

Using a behavioural model that looks at motivation, ability, processing (information) and social context, our research explored which messages are most strongly related to willingness to get vaccinated. The four areas of messaging that emerged are:

• Messages that focus on safety and efficacy of these ‘new’ vaccine technologies: across all groups, regardless of likelihood of getting vaccinated, there remains a sense of anxiety around the vaccine. An effective way to manage anxiety is to facilitate seeing other people that are known and trusted get vaccinated: building strong social norms around vaccination can help manage this effectively. Note that although anxiety does not correlate highly with likelihood to get vaccinated, it is at high levels across all groups (which is understandable but of concern).

• Creating momentum around vaccines as ‘normal behaviour’/acceptability and consistency with past actions. In many countries, less than a majority chose to be vaccinated for the flu last year; therefore, vaccination can’t be regarded as a normal part of most personal health protection routines. Changing this by showing vaccination as part of normal health routines for relevant members of a person’s community is critical to help forming and maintaining positive outcomes.

• Addressing regret: anticipated regret is a proxy for risk – this is true for not getting vaccinated but also for getting vaccinated – both need to be considered. Note that people may have low anticipated regret for not getting vaccinated if they consider incidence and severity of COVID-19 to be low (despite public health information sources suggesting otherwise).

• Build positive social identities and play to moral obligation: strong majorities consider vaccination to be their personal choice – it is important to weave this sense of autonomy into a wider pro-social identity where it is recognised that they have a choice, but their identity as a member of a wider community requires them to participate. The perception of moral obligation is held by a majority regardless of demographic profile and has a strong relationship to uptake.

• Confidence in decision versus needing more information: those with low likelihood to take up the COVID-19 vaccination are much less likely to trust information sources, with 59% overall saying they need to think hard about getting a vaccine. Public health bodies and other institutions need to understand how they can align in a way that is part of their community of understanding and builds trust, creating an environment to support critical thinking.
About Ipsos

Ipsos is the third-largest market research company in the world, present in 90 markets and employing more than 18,000 people.

Our research professionals, analysts and scientists have built unique multi-specialist capabilities that provide powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 business solutions are based on primary data coming from our surveys, social media monitoring, and qualitative or observational techniques.

“Game Changers” – our tagline – summarises our ambition to help our 5,000 clients to navigate more easily our deeply changing world.

Founded in France in 1975, Ipsos is listed on the Euronext Paris since July 1st, 1999. The company is part of the SBF 120 and the Mid-60 index and is eligible for the Deferred Settlement Service (SRD).

ISIN code FR0000073298
Reuters ISOS.PA
Bloomberg IPS:FP

www.ipsos.com

Game Changers

In our world of rapid change, the need for reliable information to make confident decisions has never been greater.

At Ipsos we believe our clients need more than a data supplier, they need a partner who can produce accurate and relevant information and turn it into actionable truth.

This is why our passionately curious experts not only provide the most precise measurement, but shape it to provide True Understanding of Society, Markets and People.

To do this we use the best of science, technology and know-how and apply the principles of security, simplicity, speed and substance to everything we do.

So that our clients can act faster, smarter and bolder.

Ultimately, success comes down to a simple truth:

YOU ACT BETTER WHEN YOU ARE SURE.
Data from the report are drawn from Essentials which tracks the public’s latest attitudes, behaviours and future intentions as the world emerges from this crisis.

The study has been designed to help businesses adapt, plan and execute in these turbulent times. It offers fast, cost-effective answers to help you navigate as consumer attitudes and behaviours continue to evolve.

Contact:

Natalie Lacey
Natalie.Lacey@ipsos.com